ACADIA Pharmaceuticals Inc. , a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

  • Hedge Funds Never Been This Bullish On ACADIA Pharmaceuticals Inc. (ACAD)
    on September 7, 2020 at 9:15 pm

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F

  • (ACAD) Alert: Johnson Fistel Announces Shareholder Class Action Against ACADIA Pharmaceuticals Survives Motion to Dismiss; Should Management be Held Accountable for Investors Losses?
    on September 5, 2020 at 12:47 pm

    Johnson Fistel, LLP is investigating potential claims on behalf of ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD) ("ACADIA" or the "Company") against certain of its officers and directors. Specifically, a class-action lawsuit pending in the United States District Court for the Southern District of California against ACADIA and certain of its current and former officers recently survived, in part, certain defendants' attempts to have the case dismissed.

  • Acadia (ACAD) Down 12% Since Last Earnings Report: Can It Rebound?
    on September 4, 2020 at 3:31 pm

    Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
    on September 2, 2020 at 1:00 pm

    ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming virtual investor conferences:

  • ACADIA Pharmaceuticals Appoints Gudarz Davar, M.D., as Executive Vice President and Head of Research and Development
    on August 31, 2020 at 1:00 pm

    ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Gudarz Davar as Executive Vice President and Head of Research and Development. Dr. Davar will be responsible for leading research and development activities at ACADIA and will serve as a member of the company’s Executive Management Committee. In this role, he will report to Serge Stankovic, M.D., M.S.P.H., President of ACADIA. Dr. Stankovic will continue to oversee research and development, regulatory, medical affairs, external innovation and pharmacovigilance functions for the company.

  • 5 Biotech Stocks That Could Be Worth a Look
    on August 27, 2020 at 2:44 am

    Newly-hired analyst Danielle Brill launched coverage at Raymond James this week with a 490-page survey of her favorite biotech stocks. These are her favorites.

  • ACADIA Acquires CerSci Therapeutics to Boost Pain Portfolio
    on August 26, 2020 at 5:01 pm

    ACADIA (ACAD) purchases CerSci Therapeutics and in turn, secures the global rights to a suite of novel compounds for neurological disorders comprising non-opioid therapies for acute and chronic pain.

  • Benzinga's Top Upgrades, Downgrades For August 25, 2020
    on August 25, 2020 at 1:35 pm

    Upgrades * According to Telsey Advisory Group, the prior rating for Burlington Stores Inc (NYSE: BURL) was changed from Market Perform to Outperform. In the first quarter, Burlington Stores showed an EPS of $4.76, compared to $1.26 from the year-ago quarter. At the moment, the stock has a 52-week-high of $250.89 and a 52-week-low of $105.67. Burlington Stores closed at $194.23 at the end of the last trading period. * According to Citigroup, the prior rating for Gap Inc (NYSE: GPS) was changed from Neutral to Buy. For the first quarter, Gap had an EPS of $2.51, compared to year-ago quarter EPS of $0.24. The current stock performance of Gap shows a 52-week-high of $19.86 and a 52-week-low of $5.26. Moreover, at the end of the last trading period, the closing price was at $15.51. * For L Brands Inc (NYSE: LB), MKM Partners upgraded the previous rating of Neutral to the current rating Buy. For the second quarter, L Brands had an EPS of $0.25, compared to year-ago quarter EPS of $0.24. The current stock performance of L Brands shows a 52-week-high of $31.33 and a 52-week-low of $8.00. Moreover, at the end of the last trading period, the closing price was at $29.63. * According to UBS, the prior rating for NIO Inc (NYSE: NIO) was changed from Sell to Neutral. NIO earned $0.15 in the second quarter, compared to $0.45 in the year-ago quarter. At the moment, the stock has a 52-week-high of $16.44 and a 52-week-low of $1.19. NIO closed at $14.97 at the end of the last trading period. * For Starbucks Corp (NASDAQ: SBUX), Stifel upgraded the previous rating of Hold to the current rating Buy. For the third quarter, Starbucks had an EPS of $0.46, compared to year-ago quarter EPS of $0.78. The stock has a 52-week-high of $98.14 and a 52-week-low of $50.02. At the end of the last trading period, Starbucks closed at $78.68. * For Crocs Inc (NASDAQ: CROX), B. Riley FBR upgraded the previous rating of Neutral to the current rating Buy. In the second quarter, Crocs showed an EPS of $1.01, compared to $0.59 from the year-ago quarter. The current stock performance of Crocs shows a 52-week-high of $43.79 and a 52-week-low of $8.40. Moreover, at the end of the last trading period, the closing price was at $39.34. * According to CIBC, the prior rating for Mercer International Inc (NASDAQ: MERC) was changed from Neutral to Outperformer. Mercer International earned $0.13 in the second quarter, compared to $0.16 in the year-ago quarter. The stock has a 52-week-high of $13.62 and a 52-week-low of $6.42. At the end of the last trading period, Mercer International closed at $8.00. Downgrades * For Portland General Electric Co (NYSE: POR), B of A Securities downgraded the previous rating of Buy to the current rating Neutral. Portland General Electric earned $0.43 in the second quarter, compared to $0.28 in the year-ago quarter. The stock has a 52-week-high of $63.08 and a 52-week-low of $37.83. At the end of the last trading period, Portland General Electric closed at $41.96. * Jefferies downgraded the previous rating for Galapagos NV (NASDAQ: GLPG) from Buy to Hold. In the second quarter, Galapagos showed an EPS of $1.95, compared to $0.96 from the year-ago quarter. The stock has a 52-week-high of $274.03 and a 52-week-low of $112.00. At the end of the last trading period, Galapagos closed at $134.83. * According to Atlantic Equities, the prior rating for Nutrien Ltd (NYSE: NTR) was changed from Overweight to Neutral. For the second quarter, Nutrien had an EPS of $1.45, compared to year-ago quarter EPS of $1.58. The current stock performance of Nutrien shows a 52-week-high of $52.41 and a 52-week-low of $23.85. Moreover, at the end of the last trading period, the closing price was at $39.06. * Stifel downgraded the previous rating for Old Dominion Freight Line Inc (NASDAQ: ODFL) from Hold to Sell. Old Dominion Freight Line earned $1.25 in the second quarter, compared to $2.16 in the year-ago quarter. At the moment, the stock has a 52-week-high of $227.21 and a 52-week-low of $119.01. Old Dominion Freight Line closed at $198.83 at the end of the last trading period. * For Momenta Pharmaceuticals Inc (NASDAQ: MNTA), HC Wainwright & Co. downgraded the previous rating of Buy to the current rating Neutral. In the second quarter, Momenta Pharmaceuticals showed an EPS of $0.48, compared to $1.16 from the year-ago quarter. The current stock performance of Momenta Pharmaceuticals shows a 52-week-high of $52.32 and a 52-week-low of $11.91. Moreover, at the end of the last trading period, the closing price was at $52.15. Initiations * Aegis Capital initiated coverage on MICT Inc (NASDAQ: MICT) with a Buy rating. The price target for MICT is set to $6.00. In the second quarter, MICT showed an EPS of $0.00, compared to $0.10 from the year-ago quarter. At the moment, the stock has a 52-week-high of $8.45 and a 52-week-low of $0.38. MICT closed at $3.59 at the end of the last trading period. * Truist Securities initiated coverage on Forte Biosciences Inc (NASDAQ: FBRX) with a Buy rating. The price target for Forte Biosciences is set to $70.00. The stock has a 52-week-high of $25.49 and a 52-week-low of $17.90. At the end of the last trading period, Forte Biosciences closed at $24.70. * With a current rating of Overweight, Wells Fargo initiated coverage on NXP Semiconductors NV (NASDAQ: NXPI). The price target seems to have been set at $145.00 for NXP Semiconductors. In the second quarter, NXP Semiconductors showed an EPS of $0.91, compared to $1.91 from the year-ago quarter. The current stock performance of NXP Semiconductors shows a 52-week-high of $139.59 and a 52-week-low of $58.41. Moreover, at the end of the last trading period, the closing price was at $123.78. * Ladenburg Thalmann initiated coverage on Synchronoss Technologies Inc (NASDAQ: SNCR) with a Buy rating. The price target for Synchronoss Technologies is set to $8.00. In the second quarter, Synchronoss Technologies showed an EPS of $0.16, compared to $0.28 from the year-ago quarter. The current stock performance of Synchronoss Technologies shows a 52-week-high of $8.78 and a 52-week-low of $2.17. Moreover, at the end of the last trading period, the closing price was at $4.39. * With a current rating of Buy, B of A Securities initiated coverage on Vasta Platform Ltd (NASDAQ: VSTA). The price target seems to have been set at $21.50 for Vasta Platform. Vasta Platform earned $0.12 in the second quarter. At the moment, the stock has a 52-week-high of $19.43 and a 52-week-low of $15.31. Vasta Platform closed at $16.02 at the end of the last trading period. * Stifel initiated coverage on Vital Farms Inc (NASDAQ: VITL) with a Buy rating. The price target for Vital Farms is set to $43.00. The stock has a 52-week-high of $43.30 and a 52-week-low of $34.51. At the end of the last trading period, Vital Farms closed at $39.38. * With a current rating of Outperform, Raymond James initiated coverage on ACADIA Pharmaceuticals Inc (NASDAQ: ACAD). The price target seems to have been set at $65.00 for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals earned $0.27 in the second quarter, compared to $0.38 in the year-ago quarter. The stock has a 52-week-high of $58.72 and a 52-week-low of $23.77. At the end of the last trading period, ACADIA Pharmaceuticals closed at $38.00. * Raymond James initiated coverage on argenx SE (NASDAQ: ARGX) with an Outperform rating. The price target for argenx is set to $257.00. For the second quarter, argenx had an EPS of $3.15, compared to year-ago quarter EPS of $1.12. The current stock performance of argenx shows a 52-week-high of $272.74 and a 52-week-low of $103.75. Moreover, at the end of the last trading period, the closing price was at $232.77. * 86 Research initiated coverage on Baozun Inc (NASDAQ: BZUN) with a Hold rating. The price target for Baozun is set to $43.00. In the second quarter, Baozun showed an EPS of $0.34, compared to $0.21 from the year-ago quarter. The stock has a 52-week-high of $50.33 and a 52-week-low of $22.19. At the end of the last trading period, Baozun closed at $40.99. * Raymond James initiated coverage on Global Blood Therapeutics Inc (NASDAQ: GBT) with an Outperform rating. The price target for Global Blood Therapeutics is set to $115.00. For the second quarter, Global Blood Therapeutics had an EPS of $0.86, compared to year-ago quarter EPS of $1.01. The current stock performance of Global Blood Therapeutics shows a 52-week-high of $87.54 and a 52-week-low of $39.95. Moreover, at the end of the last trading period, the closing price was at $62.61. * For GW Pharmaceuticals PLC (NASDAQ: GWPH), Raymond James initiated coverage, by setting the current rating at Market Perform. GW Pharmaceuticals earned $0.02 in the third quarter, compared to $0.06 in the year-ago quarter. The stock has a 52-week-high of $151.35 and a 52-week-low of $67.98. At the end of the last trading period, GW Pharmaceuticals closed at $106.27. * Raymond James initiated coverage on Immunovant Inc (NASDAQ: IMVT) with an Outperform rating. The price target for Immunovant is set to $35.00. Immunovant earned $0.38 in the fourth quarter. The stock has a 52-week-high of $35.50 and a 52-week-low of $8.34. At the end of the last trading period, Immunovant closed at $33.48. * With a current rating of Buy, Deutsche Bank initiated coverage on Jack In The Box Inc (NASDAQ: JACK). The price target seems to have been set at $100.00 for Jack In The Box. In the third quarter, Jack In The Box showed an EPS of $1.37, compared to $1.07 from the year-ago quarter. The stock has a 52-week-high of $93.12 and a 52-week-low of $16.81. At the end of the last trading period, Jack In The Box closed at $83.36. * Raymond James initiated coverage on PTC Therapeutics Inc (NASDAQ: PTCT) with an Outperform rating. The price target for PTC Therapeutics is set to $63.00. For the second quarter, PTC Therapeutics had an EPS of $2.62, compared to year-ago quarter EPS of $0.75. The stock has a 52-week-high of $59.89 and a 52-week-low of $30.79. At the end of the last trading period, PTC Therapeutics closed at $48.04. * Raymond James initiated coverage on uniQure NV (NASDAQ: QURE) with a Strong Buy rating. The price target for uniQure is set to $75.00. For the second quarter, uniQure had an EPS of $0.96, compared to year-ago quarter EPS of $0.83. At the moment, the stock has a 52-week-high of $76.69 and a 52-week-low of $36.20. uniQure closed at $38.21 at the end of the last trading period. * Raymond James initiated coverage on Sarepta Therapeutics Inc (NASDAQ: SRPT) with an Outperform rating. The price target for Sarepta Therapeutics is set to $200.00. Sarepta Therapeutics earned $1.51 in the second quarter, compared to $0.83 in the year-ago quarter. The stock has a 52-week-high of $175.00 and a 52-week-low of $72.05. At the end of the last trading period, Sarepta Therapeutics closed at $141.20. * Morgan Stanley initiated coverage on Vasta Platform Ltd (NASDAQ: VSTA) with an Overweight rating. The price target for Vasta Platform is set to $20.00. Vasta Platform earned $0.12 in the second quarter. At the moment, the stock has a 52-week-high of $19.43 and a 52-week-low of $15.31. Vasta Platform closed at $16.02 at the end of the last trading period. * For Zogenix Inc (NASDAQ: ZGNX), Raymond James initiated coverage, by setting the current rating at Market Perform. In the second quarter, Zogenix showed an EPS of $0.96, compared to $0.89 from the year-ago quarter. The stock has a 52-week-high of $57.22 and a 52-week-low of $16.65. At the end of the last trading period, Zogenix closed at $22.93. * With a current rating of Buy, HC Wainwright & Co. initiated coverage on Kopin Corp (NASDAQ: KOPN). The price target seems to have been set at $2.00 for Kopin. Kopin earned $0.01 in the second quarter, compared to $0.05 in the year-ago quarter. The current stock performance of Kopin shows a 52-week-high of $2.16 and a 52-week-low of $0.19. Moreover, at the end of the last trading period, the closing price was at $1.37. * Jefferies initiated coverage on Vital Farms Inc (NASDAQ: VITL) with a Buy rating. The price target for Vital Farms is set to $47.00. The stock has a 52-week-high of $43.30 and a 52-week-low of $34.51. At the end of the last trading period, Vital Farms closed at $39.38.See more from Benzinga * A Look Into Gartner's Debt * Domino's Pizza: Debt Insights * How Does Amgen's Debt Look?(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio
    on August 25, 2020 at 1:00 pm

    ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the acquisition of CerSci Therapeutics, a clinical-stage biotechnology company with worldwide rights to a portfolio of novel compounds for neurological conditions, including non-opioid therapies for acute and chronic pain. The lead development program is a unique Reactive Species Decomposition Accelerant (RSDAx), a first-in-class mechanism focused on interrupting pathways that sensitize neurons to pain. The portfolio contains additional preclinical stage molecules, including brain penetrant molecules, with potential for symptomatic and disease modifying treatment utility in neurodegenerative diseases.

  • What Does ACADIA Pharmaceuticals' (NASDAQ:ACAD) CEO Pay Reveal?
    on August 24, 2020 at 11:08 am

    Steve Davis became the CEO of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in 2015, and we think it's a good time to look...

[custom-facebook-feed id=]

Get it free: FREE: Zoom Backgrounds Bundle https://stacksocial.com/sales/free-zoom-backgrounds-bundle?rid=5921417 via @StackSocial

Check out my latest article: Buy-Side M&A Strategy: Financing an Acquisition https://www.linkedin.com/pulse/buy-side-ma-strategy-financing-acquisition-ian-shanno via @LinkedIn

Corporate: a professional approach to business
Finance: about the future
Consulting: tapping outside expertise for corporate finance excellence
https://alignmt.com

Load More...

FULL NAME*

What's Your Role?*

WORK EMAIL*

COMPANY NAME*

Company Description*

HOW'D YOU HEAR ABOUT US?

DETAILS ABOUT YOUR GOALS

ACADIA Pharmaceuticals Inc.

3611 Valley Centre Drive
Suite 300
San Diego, CA 92130

+1 (858) 558-2871

www.acadia-pharm.com

September 2020
S M T W T F S
 12345
6789101112
13141516171819
20212223242526
27282930  

©2020 ALIGNMT LLC | Alignment Strategy | Mergers & Acquisitions | Investor Relations

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account